NCT00706498 - Phase II Study of BI 2536 in Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Conditions

Prostatic Neoplasms

Interventions

DRUG

BI 2536

Trial Locations (6)

1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge

1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford

1216.19.4402 Boehringer Ingelheim Investigational Site, Headington

1216.19.4406 The Christie NHS Foundation Trust, Manchester

1216.19.4404 Boehringer Ingelheim Investigational Site, Newcastle upon Tyne

1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton